Boston Scientific Acquire™ Pulmonary EBUS-FNB | 25 Ga | M00552400

The Boston Scientific Acquire™ Pulmonary (Model M00552400) is a state-of-the-art Fine Needle Biopsy (FNB) instrument engineered for 2026 standards in pulmonary diagnostics. Designed specifically for use with Olympus EBUS bronchoscopes, this 25-gauge device bridges the gap between traditional aspiration and surgical biopsy by utilizing a specialized Franseen tip geometry.

By providing a three-point puncture and fully formed cutting heels, the Acquire™ device captures high-quality, non-fragmented core samples. This is a critical advantage for clinicians requiring preserved tissue architecture for the diagnosis of lymphoma, sarcoidosis, or complex lung cancer staging.

Key Performance Features

• Franseen Tip Architecture: Features three symmetric cutting edges that provide superior stability during puncture. This geometry excels at shearing tissue into the lumen, delivering up to 20x more tissue compared to standard FNA needles.

• High-Yield Core Sampling: Designed to capture a true histological core rather than a cytologic aspirate, significantly improving the diagnostic yield for molecular testing and staging.

• Optimal Flexibility: The narrow 1.4 mm sheath maintains the flexibility of the bronchoscope even when the needle is fully advanced, allowing for easier access to difficult mediastinal lymph node stations (e.g., Station 4R or 4L).

• Universal Olympus Compatibility: Engineered for seamless integration with Olympus EBUS bronchoscopes, ensuring secure locking and precise needle extension control.

Technical Specifications

• Manufacturer: Boston Scientific

• Brand: Acquire™ Pulmonary

• Model Number: M00552400

• Needle Gauge: 25 Ga (~0.72 mm OD)

• Sheath Outer Diameter: 1.4 mm

• Min. Working Channel: 2.0 mm

• Tip Design: 3-Point Franseen Needle

• Sterility: Individually sterile-packed; Single-use

Clinical Advantages

• Improved Staging Accuracy: Enhanced tissue volume allows for more comprehensive IHC (Immunohistochemistry) and NGS (Next-Generation Sequencing), which are vital for personalized lung cancer treatment.

• Reduced Needle Passes: The high tissue acquisition rate can potentially reduce the number of passes required to reach a diagnostic "adequate" sample, decreasing procedural time and patient sedation.

• Traverse Tough Tissue: The stable puncture points are highly effective when sampling fibrotic lymph nodes or lesions located behind the thick tracheobronchial wall.

Ideal Applications

• Mediastinal Lymph Node Staging: Lung cancer diagnosis and staging (N1/N2/N3).

• Granulomatous Disease: Diagnosing Sarcoidosis where histological architecture is necessary to see non-caseating granulomas.

• Hematologic Malignancies: Sampling suspected lymphoma cases that require tissue for flow cytometry and architectural review.

Condition & Quality Assurance

• Status: NEW — Original Manufacturer's Packaging.

• Packaging (IOMPB-UPS): Inner and outer packaging are undamaged and factory-sealed, ensuring full sterile integrity for immediate medical use.

• Regulatory: Prescription-only, single-use device in active commercial distribution.